And therapeutic model

Critique psychological and related educational research and therapeutic models in relation to cultural factors and biases as they have impacted minority communities. 

Marsden, CA, Bickerdike, M, Cadogen, A-K, Wright, I, Rex, A and Fink, H (1993) Serotonergic mechanisms and animal models of anxiety. In Anxiety, Neurobiology, Clinic and Therapeutic Perspectives (Eds Hamon, M, Oilat, H and Thiebot, M-H), John Libbey Eurotext Ltd, 232, pp. 75-82. 

Ghose, A. K., Crippen, G. M. The distance geometry approach to modeling receptor sites In Comprehensive Medicinal Chemistry. The Rational Design, Mechanistic Study and Therapeutic Application of Chemical Compounds, Hansch, C.,... 

Pyrrolopyrazine 22 has an IC50 of 1.7nM against Syk [88] and significantly decreased ankle swelling in prophylactic and therapeutic rat CIA models, and micro-CT scans of ankle joints showed significant inhibition of bone erosion. While 22 is clearly a potent Syk inhibitor, no selectivity or in vitro functional data has been reported. The pyrrolopyrazine scaffold appears in a series of compounds, exemplified by 23, that are substituted in the pyrrole and pyrazine rings [89-92]. These compounds are claimed to inhibit Syk and JAK, but the limited data disclosed suggests that JAK is the dominant activity. 

Induced models are often used to the study the pathogenesis of, and therapeutic venues for relevant autoimmune diseases. Some of these models, in particular EAE and AA models, have also been proposed as means to evaluate the immunomodulatory effects of chemicals on established autoimmune diseases in the Tiered Approach of immunotoxicity testing. 

What is the therapeutic model that the professional operates under, and how does that model determine the course of treatment ... 

Duration of exposure Extremely variable depends on campaign/batch, procedure, etc. may be short daily exposure for working lifetime Dependent on therapeutic use and test model... 

BioPrint consists of a large database and a set of tools with which both the data and the models generated from the data can be accessed. The database contains structural information, in vivo and in vitro data on most of the marketed pharmaceuticals and a variety of other reference compounds. The in vitro data generated consist of panels of pharmacology and early ADME assays. The in vivo data consist of ADR data extracted from drug labels, mechanisms of action, associated therapeutic areas, pharmacokinetic (PK) data and route of administration data. 

Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 1995 72 896. 

Messerer CL, Ramsay EC, Waterhouse D, et al. Liposomal irinotecan formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 2004 10(19) 6638. 

---